Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025)

Cyclerion Therapeutics (CYCN) posted quarterly Return on Sales of 0.01% for Q3 2025, up 93.61% quarter-over-quarter from 0.18% in Q2 2025.

Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025) Analysis & Trends

Cyclerion Therapeutics' Return on Sales history runs 6 years deep, the most recent figure standing at 0.01% for Q3 2025.

In Q3 2025, Return on Sales changed N/A year-over-year to 0.01%; the TTM figure through Sep 2025 stood at 0.01% (changed N/A YoY), while the FY2022 annual figure was 0.87%, down 55.0% from the prior year.
Return on Sales for Q3 2025 stood at 0.01%, up from 0.18% in the prior quarter.
The five-year high for Return on Sales was 0.01% in Q3 2025, with the low at 2.39% in Q1 2021.
The 4-year median for Return on Sales is 0.3% (2022), against an average of 0.47%.
The sharpest annual moves came in 2021 and 2022: Return on Sales sank 216 bps in 2021, then soared 220 bps in 2022.
Cyclerion Therapeutics' Return on Sales stood at 0.3% in 2021, then fell by 19 bps to 0.35% in 2022, then slumped by 145 bps to 0.86% in 2023, then jumped by 99 bps to 0.01% in 2025.
Business Quant data shows CYCN's Return on Sales at 0.01% in Q3 2025, 0.18% in Q2 2025, and 0.18% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	138.89 Bn	131.04 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.05 Bn	78.06 Bn	3.93 Bn	0.00%
3	Argenx Se	65.56 Bn	60.38 Bn	1.37 Bn	0.00%
4	Moderna	55.46 Bn	50.32 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	0.00%
7	BioNTech SE	27.70 Bn	9.30 Bn	668.28 Mn	0.00%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	0.00%
10	Cyclerion Therapeutics	12.84 Mn	9.60 Mn	-	-

Download Data